Independent evaluation of the effects of glibenclamide on reducing progressive hemorrhagic necrosis after cervical spinal cord injury

► Independent replication of a reported pre-clinical therapy for SCI was achieved. ► Documenting pre-clinical drug efficacy depends on the injury model. ► Glibenclamide (FDA-approved anti-diabetic drug) could be used for acute SCI therapy.